April 28, 2023
Astellas Pharma’s revenue in FY2022 climbed 17.2% over the year thanks to the weaker yen and growth in its flagship prostate cancer drug Xtandi (enzalutamide), but its profits sagged due in large part to massive impairment charges. According to Astellas’...read more